Regentis Biomaterials Ltd. (AMEX: RGNT) Stock Competitors & Peer Comparison
See RGNT's competitors and their performance on the AMEX and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for RGNT and its AMEX peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RGNT | $1.19 | +1.71% | 8.1M | -0.47 | -$2.45 | N/A |
| ISRG | $452.80 | -3.36% | 160B | 47.07 | $9.62 | N/A |
| BDX | $211.88 | -0.78% | 57.7B | 16.30 | $13.00 | +1.88% |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +1.88% |
| MDLN | $39.64 | -0.30% | 34.8B | 29.06 | $1.36 | N/A |
| RMD | $235.30 | -1.68% | 33.1B | 20.40 | $11.53 | +1.06% |
| WST | $399.81 | +1.87% | 27.9B | 43.48 | $9.20 | +0.22% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| SOLV | $90.38 | +3.67% | 15.4B | 12.73 | $7.10 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +1.88% |
Stock Comparison
Intuitive Surgical, Inc. (NASDAQ: ISRG)
RGNT vs ISRG Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, ISRG has a market cap of 160B. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while ISRG trades at $452.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas ISRG's P/E ratio is 47.07. In terms of profitability, RGNT's ROE is N/A, compared to ISRG's ROE of +0.17%. Regarding short-term risk, RGNT is more volatile compared to ISRG. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check ISRG's competition here
Becton, Dickinson and Company (NYSE: BDX)
RGNT vs BDX Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, BDX has a market cap of 57.7B. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while BDX trades at $211.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas BDX's P/E ratio is 16.30. In terms of profitability, RGNT's ROE is N/A, compared to BDX's ROE of +0.04%. Regarding short-term risk, RGNT is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check BDX's competition here
Becton, Dickinson and Company (NYSE: BDXA)
RGNT vs BDXA Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas BDXA's P/E ratio is 45.70. In terms of profitability, RGNT's ROE is N/A, compared to BDXA's ROE of +0.04%. Regarding short-term risk, RGNT is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check BDXA's competition here
Medline Inc. (NASDAQ: MDLN)
RGNT vs MDLN Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, MDLN has a market cap of 34.8B. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while MDLN trades at $39.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas MDLN's P/E ratio is 29.06. In terms of profitability, RGNT's ROE is N/A, compared to MDLN's ROE of +0.05%. Regarding short-term risk, RGNT is more volatile compared to MDLN. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check MDLN's competition here
ResMed Inc. (NYSE: RMD)
RGNT vs RMD Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, RMD has a market cap of 33.1B. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while RMD trades at $235.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas RMD's P/E ratio is 20.40. In terms of profitability, RGNT's ROE is N/A, compared to RMD's ROE of +0.25%. Regarding short-term risk, RGNT is more volatile compared to RMD. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check RMD's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
RGNT vs WST Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, WST has a market cap of 27.9B. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while WST trades at $399.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas WST's P/E ratio is 43.48. In terms of profitability, RGNT's ROE is N/A, compared to WST's ROE of +0.21%. Regarding short-term risk, RGNT is more volatile compared to WST. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
RGNT vs HOLX Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas HOLX's P/E ratio is 31.54. In terms of profitability, RGNT's ROE is N/A, compared to HOLX's ROE of +0.11%. Regarding short-term risk, RGNT is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check HOLX's competition here
Solventum Corporation (NYSE: SOLV)
RGNT vs SOLV Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, SOLV has a market cap of 15.4B. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while SOLV trades at $90.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas SOLV's P/E ratio is 12.73. In terms of profitability, RGNT's ROE is N/A, compared to SOLV's ROE of +0.03%. Regarding short-term risk, RGNT is less volatile compared to SOLV. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check SOLV's competition here
Becton, Dickinson and Company (NYSE: BDXB)
RGNT vs BDXB Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas BDXB's P/E ratio is 7.60. In terms of profitability, RGNT's ROE is N/A, compared to BDXB's ROE of +0.04%. Regarding short-term risk, RGNT is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
RGNT vs BAX Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, BAX has a market cap of 13.3B. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while BAX trades at $25.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas BAX's P/E ratio is 12.39. In terms of profitability, RGNT's ROE is N/A, compared to BAX's ROE of -0.12%. Regarding short-term risk, RGNT is more volatile compared to BAX. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check BAX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
RGNT vs COO Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, COO has a market cap of 11.9B. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while COO trades at $62.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas COO's P/E ratio is 13.67. In terms of profitability, RGNT's ROE is N/A, compared to COO's ROE of +0.07%. Regarding short-term risk, RGNT is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check COO's competition here
Repligen Corporation (NASDAQ: RGEN)
RGNT vs RGEN Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, RGEN has a market cap of 11.1B. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while RGEN trades at $173.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas RGEN's P/E ratio is 96.38. In terms of profitability, RGNT's ROE is N/A, compared to RGEN's ROE of -0.01%. Regarding short-term risk, RGNT is more volatile compared to RGEN. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check RGEN's competition here
Avantor, Inc. (NYSE: AVTR)
RGNT vs AVTR Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, AVTR has a market cap of 10.5B. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while AVTR trades at $15.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas AVTR's P/E ratio is 18.19. In terms of profitability, RGNT's ROE is N/A, compared to AVTR's ROE of +0.06%. Regarding short-term risk, RGNT is more volatile compared to AVTR. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check AVTR's competition here
AptarGroup, Inc. (NYSE: ATR)
RGNT vs ATR Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, ATR has a market cap of 9B. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while ATR trades at $142.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas ATR's P/E ratio is 24.92. In terms of profitability, RGNT's ROE is N/A, compared to ATR's ROE of +0.10%. Regarding short-term risk, RGNT is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check ATR's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
RGNT vs BLCO Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, BLCO has a market cap of 7.1B. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while BLCO trades at $19.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas BLCO's P/E ratio is 30.72. In terms of profitability, RGNT's ROE is N/A, compared to BLCO's ROE of -0.02%. Regarding short-term risk, RGNT is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check BLCO's competition here
Teleflex Incorporated (NYSE: TFX)
RGNT vs TFX Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, TFX has a market cap of 6.4B. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while TFX trades at $150.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas TFX's P/E ratio is 17.22. In terms of profitability, RGNT's ROE is N/A, compared to TFX's ROE of +0.10%. Regarding short-term risk, RGNT is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check TFX's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
RGNT vs MMSI Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, MMSI has a market cap of 5.2B. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while MMSI trades at $87.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas MMSI's P/E ratio is 22.30. In terms of profitability, RGNT's ROE is N/A, compared to MMSI's ROE of +0.10%. Regarding short-term risk, RGNT is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
RGNT vs ICUI Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, ICUI has a market cap of 4.3B. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while ICUI trades at $172.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas ICUI's P/E ratio is 21.53. In terms of profitability, RGNT's ROE is N/A, compared to ICUI's ROE of +0.03%. Regarding short-term risk, RGNT is less volatile compared to ICUI. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check ICUI's competition here
Envista Holdings Corp (NYSE: NVST)
RGNT vs NVST Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, NVST has a market cap of 4B. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while NVST trades at $25.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas NVST's P/E ratio is 17.13. In terms of profitability, RGNT's ROE is N/A, compared to NVST's ROE of +0.21%. Regarding short-term risk, RGNT is more volatile compared to NVST. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check NVST's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
RGNT vs PLSE Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, PLSE has a market cap of 3.8B. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while PLSE trades at $53.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas PLSE's P/E ratio is -45.08. In terms of profitability, RGNT's ROE is N/A, compared to PLSE's ROE of -0.78%. Regarding short-term risk, RGNT is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check PLSE's competition here
Stevanato Group S.p.A. (NYSE: STVN)
RGNT vs STVN Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, STVN has a market cap of 3.7B. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while STVN trades at $13.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas STVN's P/E ratio is 20.50. In terms of profitability, RGNT's ROE is N/A, compared to STVN's ROE of +0.09%. Regarding short-term risk, RGNT is less volatile compared to STVN. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check STVN's competition here
AtriCure, Inc. (NASDAQ: ATRC)
RGNT vs ATRC Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, ATRC has a market cap of 3B. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while ATRC trades at $58.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas ATRC's P/E ratio is 1817.08. In terms of profitability, RGNT's ROE is N/A, compared to ATRC's ROE of +0.03%. Regarding short-term risk, RGNT is more volatile compared to ATRC. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check ATRC's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
RGNT vs BLFS Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, BLFS has a market cap of 1.9B. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while BLFS trades at $38.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas BLFS's P/E ratio is 37.49. In terms of profitability, RGNT's ROE is N/A, compared to BLFS's ROE of +0.13%. Regarding short-term risk, RGNT is more volatile compared to BLFS. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check BLFS's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
RGNT vs XRAY Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, XRAY has a market cap of 1.9B. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while XRAY trades at $9.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas XRAY's P/E ratio is 6.62. In terms of profitability, RGNT's ROE is N/A, compared to XRAY's ROE of -0.09%. Regarding short-term risk, RGNT is less volatile compared to XRAY. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
RGNT vs LMAT Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, LMAT has a market cap of 1.9B. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while LMAT trades at $80.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas LMAT's P/E ratio is 29.76. In terms of profitability, RGNT's ROE is N/A, compared to LMAT's ROE of +0.15%. Regarding short-term risk, RGNT is more volatile compared to LMAT. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check LMAT's competition here
Azenta, Inc. (NASDAQ: AZTA)
RGNT vs AZTA Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, AZTA has a market cap of 1.7B. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while AZTA trades at $39.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas AZTA's P/E ratio is 93.33. In terms of profitability, RGNT's ROE is N/A, compared to AZTA's ROE of -0.08%. Regarding short-term risk, RGNT is less volatile compared to AZTA. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
RGNT vs KMTS Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, KMTS has a market cap of 1.7B. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while KMTS trades at $28.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas KMTS's P/E ratio is -10.86. In terms of profitability, RGNT's ROE is N/A, compared to KMTS's ROE of -0.64%. Regarding short-term risk, RGNT is more volatile compared to KMTS. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
RGNT vs STAA Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, STAA has a market cap of 1.3B. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while STAA trades at $25.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas STAA's P/E ratio is 44.23. In terms of profitability, RGNT's ROE is N/A, compared to STAA's ROE of +0.00%. Regarding short-term risk, RGNT is less volatile compared to STAA. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check STAA's competition here
Atrion Corporation (NASDAQ: ATRI)
RGNT vs ATRI Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas ATRI's P/E ratio is 64.50. In terms of profitability, RGNT's ROE is N/A, compared to ATRI's ROE of +0.08%. Regarding short-term risk, RGNT is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check ATRI's competition here
MiniMed Group, Inc. (NASDAQ: MMEDV)
RGNT vs MMEDV Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, MMEDV has a market cap of 495.6M. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while MMEDV trades at $17.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas MMEDV's P/E ratio is N/A. In terms of profitability, RGNT's ROE is N/A, compared to MMEDV's ROE of N/A. Regarding short-term risk, RGNT is more volatile compared to MMEDV. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check MMEDV's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
RGNT vs ANGO Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, ANGO has a market cap of 493.1M. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while ANGO trades at $11.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas ANGO's P/E ratio is -30.06. In terms of profitability, RGNT's ROE is N/A, compared to ANGO's ROE of -0.19%. Regarding short-term risk, RGNT is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check ANGO's competition here
Embecta Corp. (NASDAQ: EMBC)
RGNT vs EMBC Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, EMBC has a market cap of 350M. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while EMBC trades at $6.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas EMBC's P/E ratio is 2.38. In terms of profitability, RGNT's ROE is N/A, compared to EMBC's ROE of -0.14%. Regarding short-term risk, RGNT is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check EMBC's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
RGNT vs SMTI Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, SMTI has a market cap of 289.9M. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while SMTI trades at $31.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas SMTI's P/E ratio is -525.83. In terms of profitability, RGNT's ROE is N/A, compared to SMTI's ROE of -4.74%. Regarding short-term risk, RGNT is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check SMTI's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
RGNT vs OSUR Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, OSUR has a market cap of 237.9M. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while OSUR trades at $3.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas OSUR's P/E ratio is -5.00. In terms of profitability, RGNT's ROE is N/A, compared to OSUR's ROE of -0.15%. Regarding short-term risk, RGNT is less volatile compared to OSUR. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check OSUR's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
RGNT vs UTMD Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, UTMD has a market cap of 230.4M. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while UTMD trades at $72.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas UTMD's P/E ratio is 21.48. In terms of profitability, RGNT's ROE is N/A, compared to UTMD's ROE of +0.09%. Regarding short-term risk, RGNT is more volatile compared to UTMD. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check UTMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
RGNT vs PDEX Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, PDEX has a market cap of 201M. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while PDEX trades at $63.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas PDEX's P/E ratio is 17.21. In terms of profitability, RGNT's ROE is N/A, compared to PDEX's ROE of +0.26%. Regarding short-term risk, RGNT is more volatile compared to PDEX. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check PDEX's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
RGNT vs NNNN Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, NNNN has a market cap of 169M. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while NNNN trades at $3.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas NNNN's P/E ratio is 25.67. In terms of profitability, RGNT's ROE is N/A, compared to NNNN's ROE of +0.27%. Regarding short-term risk, RGNT is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check NNNN's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
RGNT vs KRMD Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, KRMD has a market cap of 141.7M. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while KRMD trades at $3.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas KRMD's P/E ratio is -77.12. In terms of profitability, RGNT's ROE is N/A, compared to KRMD's ROE of -0.11%. Regarding short-term risk, RGNT is less volatile compared to KRMD. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check KRMD's competition here
Stereotaxis, Inc. (AMEX: STXS)
RGNT vs STXS Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, STXS has a market cap of 111.2M. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while STXS trades at $1.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas STXS's P/E ratio is -6.53. In terms of profitability, RGNT's ROE is N/A, compared to STXS's ROE of -1.33%. Regarding short-term risk, RGNT is less volatile compared to STXS. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check STXS's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
RGNT vs AKYA Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas AKYA's P/E ratio is -1.34. In terms of profitability, RGNT's ROE is N/A, compared to AKYA's ROE of -1.80%. Regarding short-term risk, RGNT is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check AKYA's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
RGNT vs POCI Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, POCI has a market cap of 53.8M. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while POCI trades at $4.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas POCI's P/E ratio is -10.66. In terms of profitability, RGNT's ROE is N/A, compared to POCI's ROE of -0.24%. Regarding short-term risk, RGNT is more volatile compared to POCI. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check POCI's competition here
SkyAI, Inc. (NASDAQ: STSS)
RGNT vs STSS Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while STSS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas STSS's P/E ratio is -0.02. In terms of profitability, RGNT's ROE is N/A, compared to STSS's ROE of -1.54%. Regarding short-term risk, RGNT is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check STSS's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
RGNT vs OMIC Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas OMIC's P/E ratio is -0.58. In terms of profitability, RGNT's ROE is N/A, compared to OMIC's ROE of -0.43%. Regarding short-term risk, RGNT is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
RGNT vs IGAP Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas IGAP's P/E ratio is -10.52. In terms of profitability, RGNT's ROE is N/A, compared to IGAP's ROE of +1.80%. Regarding short-term risk, RGNT is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check IGAP's competition here
Daxor Corporation (NASDAQ: DXR)
RGNT vs DXR Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, DXR has a market cap of 49.4M. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while DXR trades at $8.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas DXR's P/E ratio is 6.88. In terms of profitability, RGNT's ROE is N/A, compared to DXR's ROE of +0.13%. Regarding short-term risk, RGNT is more volatile compared to DXR. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check DXR's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
RGNT vs HBIO Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, HBIO has a market cap of 38.2M. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while HBIO trades at $8.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas HBIO's P/E ratio is -23.31. In terms of profitability, RGNT's ROE is N/A, compared to HBIO's ROE of -0.92%. Regarding short-term risk, RGNT is more volatile compared to HBIO. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check HBIO's competition here
Nephros, Inc. (NASDAQ: NEPH)
RGNT vs NEPH Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, NEPH has a market cap of 30.6M. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while NEPH trades at $2.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas NEPH's P/E ratio is 46.92. In terms of profitability, RGNT's ROE is N/A, compared to NEPH's ROE of +0.17%. Regarding short-term risk, RGNT is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check NEPH's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
RGNT vs SDC Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas SDC's P/E ratio is -0.03. In terms of profitability, RGNT's ROE is N/A, compared to SDC's ROE of -1.96%. Regarding short-term risk, RGNT is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check SDC's competition here
Milestone Scientific Inc. (AMEX: MLSS)
RGNT vs MLSS Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, MLSS has a market cap of 27.5M. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while MLSS trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas MLSS's P/E ratio is -6.07. In terms of profitability, RGNT's ROE is N/A, compared to MLSS's ROE of -1.49%. Regarding short-term risk, RGNT is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check MLSS's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
RGNT vs ZJYL Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, ZJYL has a market cap of 26.1M. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while ZJYL trades at $3.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas ZJYL's P/E ratio is 22.78. In terms of profitability, RGNT's ROE is N/A, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, RGNT is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check ZJYL's competition here
Invacare Corporation (NYSE: IVC)
RGNT vs IVC Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas IVC's P/E ratio is -0.79. In terms of profitability, RGNT's ROE is N/A, compared to IVC's ROE of -0.46%. Regarding short-term risk, RGNT is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
RGNT vs RVP Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, RVP has a market cap of 16.9M. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while RVP trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas RVP's P/E ratio is -4.69. In terms of profitability, RGNT's ROE is N/A, compared to RVP's ROE of -0.05%. Regarding short-term risk, RGNT is more volatile compared to RVP. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check RVP's competition here
Bionano Genomics, Inc. (NASDAQ: BNGO)
RGNT vs BNGO Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, BNGO has a market cap of 13.5M. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while BNGO trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas BNGO's P/E ratio is -0.38. In terms of profitability, RGNT's ROE is N/A, compared to BNGO's ROE of -0.79%. Regarding short-term risk, RGNT is more volatile compared to BNGO. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check BNGO's competition here
Femasys Inc. (NASDAQ: FEMY)
RGNT vs FEMY Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, FEMY has a market cap of 11.6M. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while FEMY trades at $1.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas FEMY's P/E ratio is -0.31. In terms of profitability, RGNT's ROE is N/A, compared to FEMY's ROE of -2.26%. Regarding short-term risk, RGNT is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check FEMY's competition here
Lucyd, Inc (NASDAQ: LUCY)
RGNT vs LUCY Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, LUCY has a market cap of 7.2M. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while LUCY trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas LUCY's P/E ratio is -0.64. In terms of profitability, RGNT's ROE is N/A, compared to LUCY's ROE of -0.89%. Regarding short-term risk, RGNT is more volatile compared to LUCY. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check LUCY's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
RGNT vs NSTG Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas NSTG's P/E ratio is -0.03. In terms of profitability, RGNT's ROE is N/A, compared to NSTG's ROE of -1.43%. Regarding short-term risk, RGNT is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check NSTG's competition here
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (NASDAQ: CUPR)
RGNT vs CUPR Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, CUPR has a market cap of 4.8M. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while CUPR trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas CUPR's P/E ratio is -1.31. In terms of profitability, RGNT's ROE is N/A, compared to CUPR's ROE of -0.85%. Regarding short-term risk, RGNT is more volatile compared to CUPR. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check CUPR's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
RGNT vs POAI Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas POAI's P/E ratio is -0.38. In terms of profitability, RGNT's ROE is N/A, compared to POAI's ROE of -21.19%. Regarding short-term risk, RGNT is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check POAI's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
RGNT vs MHUA Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas MHUA's P/E ratio is 0.25. In terms of profitability, RGNT's ROE is N/A, compared to MHUA's ROE of +0.07%. Regarding short-term risk, RGNT is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check MHUA's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
RGNT vs GMVD Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas GMVD's P/E ratio is -0.01. In terms of profitability, RGNT's ROE is N/A, compared to GMVD's ROE of +2.09%. Regarding short-term risk, RGNT is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
RGNT vs GMVDW Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas GMVDW's P/E ratio is N/A. In terms of profitability, RGNT's ROE is N/A, compared to GMVDW's ROE of +3.68%. Regarding short-term risk, RGNT is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check GMVDW's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
RGNT vs NXGL Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, NXGL has a market cap of 1.7M. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while NXGL trades at $3.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas NXGL's P/E ratio is -5.01. In terms of profitability, RGNT's ROE is N/A, compared to NXGL's ROE of -1.33%. Regarding short-term risk, RGNT is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check NXGL's competition here
Avinger, Inc. (NASDAQ: AVGR)
RGNT vs AVGR Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas AVGR's P/E ratio is -0.05. In terms of profitability, RGNT's ROE is N/A, compared to AVGR's ROE of +17.82%. Regarding short-term risk, RGNT is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check AVGR's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
RGNT vs NXGLW Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, NXGLW has a market cap of 496.3K. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while NXGLW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas NXGLW's P/E ratio is -0.01. In terms of profitability, RGNT's ROE is N/A, compared to NXGLW's ROE of -1.33%. Regarding short-term risk, RGNT is less volatile compared to NXGLW. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check NXGLW's competition here
Lucyd, Inc (NASDAQ: LUCYW)
RGNT vs LUCYW Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas LUCYW's P/E ratio is N/A. In terms of profitability, RGNT's ROE is N/A, compared to LUCYW's ROE of -0.89%. Regarding short-term risk, RGNT is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check LUCYW's competition here
Apria, Inc. (NASDAQ: APR)
RGNT vs APR Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, APR has a market cap of 0. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas APR's P/E ratio is 22.59. In terms of profitability, RGNT's ROE is N/A, compared to APR's ROE of +9.81%. Regarding short-term risk, RGNT is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check APR's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
RGNT vs ATRS Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas ATRS's P/E ratio is 14.95. In terms of profitability, RGNT's ROE is N/A, compared to ATRS's ROE of +0.31%. Regarding short-term risk, RGNT is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check ATRS's competition here
IntriCon Corporation (NASDAQ: IIN)
RGNT vs IIN Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, IIN has a market cap of 0. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas IIN's P/E ratio is 226.45. In terms of profitability, RGNT's ROE is N/A, compared to IIN's ROE of -0.00%. Regarding short-term risk, RGNT is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check IIN's competition here
Analogic Corporation (NASDAQ: ALOG)
RGNT vs ALOG Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, ALOG has a market cap of 0. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas ALOG's P/E ratio is 40.93. In terms of profitability, RGNT's ROE is N/A, compared to ALOG's ROE of -0.15%. Regarding short-term risk, RGNT is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check ALOG's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
RGNT vs HRC Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, HRC has a market cap of 0. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas HRC's P/E ratio is 41.92. In terms of profitability, RGNT's ROE is N/A, compared to HRC's ROE of +0.14%. Regarding short-term risk, RGNT is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check HRC's competition here
Invuity, Inc. (NASDAQ: IVTY)
RGNT vs IVTY Comparison November 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 8.1M. In comparison, IVTY has a market cap of 0. Regarding current trading prices, RGNT is priced at $1.19 on the AMEX, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.47, whereas IVTY's P/E ratio is -3.80. In terms of profitability, RGNT's ROE is N/A, compared to IVTY's ROE of -2.40%. Regarding short-term risk, RGNT is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check IVTY's competition here